The shares of next-generation vaccine developer Novavax (NVAX.US) have come under pressure in the face of a $125 million offer to sell common stock. The funds from the sale are expected to inject into the company's budget and expenses. The company intends to grant 30-day options to purchase up to $18.75 million in additional common shares:
- J.P. Morgan, Jefferies and Cowen have been selected to act as underwriters of the common stock offering. Concurrent with the common stock offering, Novavax also announced a $125 million offering of convertible notes due 2027.
- The company is likely to use the net proceeds from the stock and bond offerings for general corporate purposes, including the flotation of Nuvaxovid and the repayment or repurchase of a portion of the $325 million in debt.
Novavax (NVAX.US) shares, M30 interval. Novavax shares are close to price levels that have proven to be strong support levels since the beginning of 2000 and have indicated an imminent unwinding of the company's share price. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
